Cytosorbents logo

CTSO - Cytosorbents Share Price

$9.67 -0.1  -0.6%

Last Trade - 28/05/20

Sector
Healthcare
Size
Small Cap
Market Cap £287.6m
Enterprise Value £278.4m
Revenue £23.2m
Position in Universe 3131st / 6361
Bullish
Bearish
Unlock CTSO Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Financial Summary
FINANCIAL BRIEF: : For the three months ended 31 March 2020, Cytosorbents Corp revenues increased 68% to $8.7M. Net loss decreased 29% to $3.5M. Revenues reflect CytoSorb sales increase of 81% to $8.2M. Lower net loss reflects Research and development decrease of 19% to $2M (expense), Legal, financial and other consulting decrease of 8% to $519K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.15 to -$0.10.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

CTSO Revenue Unlock CTSO Revenue

Net Income

CTSO Net Income Unlock CTSO Revenue

Normalised EPS

CTSO Normalised EPS Unlock CTSO Revenue

PE Ratio Range

CTSO PE Ratio Range Unlock CTSO Revenue

Dividend Yield Range

CTSO Dividend Yield Range Unlock CTSO Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
CTSO EPS Forecasts Unlock CTSO Revenue
Profile Summary

CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company's purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company's CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery, autoimmune disease flares, cancer, cytokine release syndrome in cancer immunotherapy and cancer cachexia.

Directors
Last Annual December 31st, 2019
Last Interim March 31st, 2020
Incorporated October 28, 2014
Public Since June 17, 2005
No. of Shareholders: 8,400
No. of Employees: 151
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index Nasdaq Composite ,
Exchange NASDAQ Capital Market
Shares in Issue 36,231,035
Free Float (0.0%)
Eligible for
ISAs
SIPPs
CTSO Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for CTSO
Upcoming Events for CTSO
Tuesday 2nd June, 2020
Cytosorbents Corp Annual Shareholders Meeting
Wednesday 3rd June, 2020
Cytosorbents Corp at Jefferies Healthcare Conference (Virtual)
Frequently Asked Questions for Cytosorbents
What is the Cytosorbents share price?

As of 28/05/20, shares in Cytosorbents are trading at $9.67, giving the company a market capitalisation of £287.6m. This share price information is delayed by 15 minutes.

How has the Cytosorbents share price performed this year?

Shares in Cytosorbents are currently trading at $9.67 and the price has moved by 45.15% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Cytosorbents price has moved by 35.02% over the past year.

What are the analyst and broker recommendations for Cytosorbents?

Of the analysts with advisory recommendations for Cytosorbents, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Cytosorbents is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Cytosorbents next release its financial results?

Cytosorbents is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the Cytosorbents dividend yield?

Cytosorbents does not currently pay a dividend.

Does Cytosorbents pay a dividend?

Cytosorbents does not currently pay a dividend.

When does Cytosorbents next pay dividends?

Cytosorbents does not currently pay a dividend.

How do I buy Cytosorbents shares?

To buy shares in Cytosorbents you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Cytosorbents?

Shares in Cytosorbents are currently trading at $9.67, giving the company a market capitalisation of £287.6m.

Where are Cytosorbents shares listed? Where are Cytosorbents shares listed?

Here are the trading details for Cytosorbents:

Country of listing: United States
Exchange: NAQ
Ticker Symbol: CTSO
What kind of share is Cytosorbents?

Based on an overall assessment of its quality, value and momentum, Cytosorbents is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Cytosorbents share price forecast 2020?

Shares in Cytosorbents are currently priced at $9.67. At that level they are trading at 26.48% discount to the analyst consensus target price of 0.00.

Analysts covering Cytosorbents currently have a consensus Earnings Per Share (EPS) forecast of -0.514 for the next financial year.

How can I tell whether the Cytosorbents share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cytosorbents. Over the past six months, the relative strength of its shares against the market has been 0.154k%. At the current price of $9.67, shares in Cytosorbents are trading at 74.07% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Cytosorbents PE Ratio?

We were not able to find PE ratio data for Cytosorbents.

Who are the key directors of Cytosorbents?

We were unable to find the directors for Cytosorbents.

Who are the major shareholders of Cytosorbents?

Here are the top five shareholders of Cytosorbents based on the size of their shareholding:

Shipley (Robert) Individual Investor
Percentage owned: 7.65% (2.77m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 5.27% (1.91m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 3.89% (1.41m shares)
Skylands Capital, LLC Hedge Fund
Percentage owned: 3.11% (1.13m shares)
Vanguard Total Stock Market Index Fund Mutual Fund
Percentage owned: 2.3% (832k shares)
Similar to CTSO
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.